A meaningful portion of Merck’s MRK revenues comes from its oncology franchise anchored by its blockbuster PD-L1 inhibitor, ...

Spherix Global Insights reports new findings from its inaugural Market Dynamix(TM): PD-1 Inhibition in Solid Tumors (US) study, based on quantitative and qualitative responses from more than 100 U.S.

Merck CEO Rob Davis expressed high confidence during the company’s J.P. Morgan presentation on Monday, revealing that the ...

US pharma major Merck (NYSE: MRK) is trying to make its looming Keytruda (pembrolizumab) patent hill look more like a speed ...

Moderna pivots to infectious disease & oncology, targeting cash break-even by 2028. Click here to see why I rate MRNA stock a ...

Rising clinical innovations, combination therapy advances, and growing cancer prevalence accelerate global and U.S. market growth.Austin, Texas, Jan. 14, 2026 (GLOBE NEWSWIRE) -- Keytruda Market Size ...

MSD awaits 20 potential launches and 80 late-stage readouts across its pipeline, which it believes will double $35bn ...

The biotech will explore the potential of BI-1808 plus Keytruda in clear cell and high-grade serous ovarian cancer subtypes.

MSD is a company that is ‘serious about science.’ In 2024, its global research and development investment reached $17.9 ...

Merck said on Monday it has raised its outlook for new growth drivers, forecasting $70 billion in revenue from these fresh ...

With that as the backdrop, here's a rundown of three dividend stocks to buy with plans to only hold them for the next 10 ...

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced positive topline results from the Phase ...